How the Immune System Responds to Breast Cancer Cells

Breast cancer is a group of diseases in which abnormal breast cells grow and can invade nearby tissue or spread elsewhere in the body. The immune system can recognize and attack some breast cancer cells, but tumors may also evade or suppress those defenses. This interaction—known as cancer immune surveillance and immune escape—involves tumor antigens, T cells, natural killer cells, antibodies, and the tumor microenvironment. Its clinical importance is reflected in the success of some immune-based treatments, particularly for selected triple-negative breast cancers, and in the continuing effort to identify which patients are most likely to benefit.

Immune surveillance and breast cancer cell recognition

The National Cancer Institute describes immunosurveillance as the process by which the immune system detects and responds to cancer cells. In breast cancer, this response is not a single attack: immune cells recognize abnormal signals, coordinate inflammation, and may kill tumor cells, while cancer cells can adapt to avoid detection. The outcome varies with tumor subtype, genetic changes, immune-cell composition, and treatment history.

A useful framework is cancer immunoediting: elimination, equilibrium, and escape. During elimination, immune defenses destroy susceptible cancer cells. If some survive, equilibrium can hold their growth in check while favoring less visible variants. In escape, tumor cells and their surroundings acquire mechanisms that weaken or divert immune responses. These stages are a conceptual model; they do not occur as a simple, measurable sequence in every patient.

How immune cells identify tumor antigens

Tumor antigens are molecules or molecular fragments that can help the immune system distinguish cancer cells from normal cells. Some arise from altered proteins produced by cancer-driving mutations; others are normal proteins made in unusual amounts or in an abnormal context. Dendritic cells can collect tumor material and present antigen fragments to T cells, helping initiate an adaptive immune response. T cells then recognize antigen fragments displayed on major histocompatibility complex molecules, called human leukocyte antigens in people.

Recognition is selective rather than automatic. A tumor may carry potential antigens without provoking a strong response if the antigens are poorly presented, the relevant T cells are absent or inhibited, or the surrounding tissue suppresses immune activity. This helps explain why tumors with similar clinical labels can differ in immune activity and treatment response.

T cells, natural killer cells, and antibodies

CD8-positive cytotoxic T cells can kill cancer cells after recognizing matching antigen–HLA complexes. CD4-positive helper T cells support immune coordination, while regulatory T cells normally restrain excessive immune reactions but can also limit antitumor activity inside tumors. Natural killer cells provide another route of attack: they can detect stressed cells or cells with reduced HLA display, a change that may help some cancers evade T cells.

Antibodies can bind targets on breast cancer cells and support immune killing or deliver a drug payload, depending on the treatment. For example, trastuzumab targets the HER2 protein and can recruit immune mechanisms in addition to blocking HER2 signaling. The American Cancer Society estimates that about 15% to 20% of breast cancers have high levels of HER2, making HER2 status an important guide to treatment rather than a universal feature of breast cancer.

The breast tumor microenvironment shapes immune response

The tumor microenvironment is the ecosystem surrounding cancer cells: immune cells, blood vessels, connective tissue, signaling molecules, and other local components. The National Cancer Institute notes that these surroundings can influence whether tumors grow, spread, or respond to treatment. In breast cancer, the presence and activity of tumor-infiltrating lymphocytes (TILs)—immune cells found within or around a tumor—provide one measure of this interaction.

Inflamed and immune-poor tumors

An “inflamed” or immune-enriched tumor contains detectable immune activity, often including T cells near cancer cells. A tumor with few infiltrating immune cells is sometimes described as immune-poor or “cold.” These labels are useful shorthand, not fixed diagnoses: immune-cell location, function, and the particular cells present all matter. The International Immuno-Oncology Biomarker Working Group has developed methods for assessing TILs in breast cancer tissue, especially in research and clinical studies.

TIL levels are often higher in triple-negative and HER2-positive breast cancers than in hormone receptor-positive, HER2-negative tumors, although substantial variation exists within each subtype. Research reviewed by the working group has linked higher TIL levels with more favorable outcomes in some early-stage triple-negative and HER2-positive settings. TILs are therefore informative biological markers, but they do not by themselves determine an individual patient’s prognosis or treatment plan.

Immune suppression and tumor escape

Breast tumors may reduce immune attack by interfering with antigen presentation, producing suppressive signals, or recruiting cells that dampen T-cell activity. Programmed death ligand 1 (PD-L1), for example, can bind the PD-1 receptor on immune cells and reduce their activity. Regulatory T cells and certain myeloid cells can also contribute to a locally suppressive environment. These mechanisms may operate together, but their importance differs between tumors.

Immune escape helps explain why the presence of immune cells does not guarantee tumor control. It also provides a rationale for checkpoint inhibitors, which block selected inhibitory signals, and for combination treatments that pair immunotherapy with chemotherapy or other medicines. The goal is not to stimulate the immune system indiscriminately, but to restore useful antitumor activity while managing the risk of immune-related side effects.

Immunotherapy and clinical evidence in breast cancer

Immunotherapy is treatment that uses or modifies immune mechanisms to fight disease. For breast cancer, established approaches include immune checkpoint inhibitors for selected patients and antibody-based treatments that direct immune or drug activity toward tumor targets. The Food and Drug Administration’s approvals illustrate an important principle: eligibility depends on cancer subtype, stage, biomarkers, and the exact treatment setting.

Checkpoint inhibitors in triple-negative breast cancer

Triple-negative breast cancer (TNBC) lacks estrogen and progesterone receptors and does not have HER2 overexpression or amplification. Because some TNBCs show substantial immune activity, checkpoint blockade has been studied in this subtype. In the phase 3 KEYNOTE-522 trial, reported by Schmid and colleagues in the New England Journal of Medicine, adding pembrolizumab to chemotherapy before surgery and continuing it after surgery improved event-free survival for patients with early-stage TNBC compared with chemotherapy alone. The FDA approved this perioperative regimen for eligible high-risk early-stage TNBC in 2021.

For locally recurrent unresectable or metastatic TNBC, the FDA approved pembrolizumab with chemotherapy for tumors expressing PD-L1 at the specified combined positive score threshold. In the phase 3 KEYNOTE-355 trial, Cortes and colleagues reported a median overall survival of 23.0 months with pembrolizumab plus chemotherapy versus 16.1 months with chemotherapy alone among patients whose tumors had a PD-L1 combined positive score of at least 10. These results apply to the studied population and regimen; they should not be generalized to all breast cancers or all patients with TNBC.

Antibody-based therapies and immune recruitment

Monoclonal antibodies recognize particular targets on or around cancer cells. Some, such as trastuzumab, inhibit a growth pathway and can also recruit immune cells through antibody-dependent cellular cytotoxicity. Antibody–drug conjugates attach a potent medicine to an antibody, helping deliver the payload to cells that carry the target. These treatments are not interchangeable with checkpoint inhibitors: they act through different mechanisms and are selected according to tumor biomarkers and clinical circumstances.

HER2-directed therapies are a prominent example of biomarker-guided treatment. A pathologist tests tumor tissue for HER2 status, and results help clinicians identify therapies likely to be relevant. This illustrates how immune biology and precision oncology intersect: the treatment decision depends not only on whether the immune system can respond, but also on whether the tumor presents a suitable target.

Limits, side effects, and ongoing research

Not all patients benefit from immunotherapy, and checkpoint inhibitors can cause immune-related inflammation affecting organs such as the skin, bowel, lungs, liver, or endocrine glands. Clinical teams weigh potential benefit against these risks and monitor patients during treatment. Biomarkers such as PD-L1 and TILs can inform research or treatment selection in specific contexts, but no single marker perfectly predicts response across breast cancer.

Researchers are investigating tumor vaccines, cellular therapies, new immune targets, and combinations intended to convert immune-poor tumors into more responsive ones. Trials also examine how immune activity changes before and after chemotherapy, surgery, radiation, or targeted therapy. These studies are important because breast cancer includes biologically distinct diseases, and a strategy effective for one subtype may not work for another.

Conclusion: Connecting recognition, tumor context, and treatment

The immune system responds to breast cancer through antigen recognition, T-cell and natural-killer-cell activity, antibodies, and signals from the tumor microenvironment. Some tumors attract active immune responses; others suppress or evade them. TIL research, HER2-directed antibodies, and checkpoint inhibitors demonstrate how understanding these mechanisms can inform care, while clinical evidence shows that immunotherapy benefits particular groups rather than every patient with breast cancer.

For further reading, consult the National Cancer Institute’s patient and professional resources, review current FDA treatment information, and discuss biomarker results and clinical-trial options with a qualified oncology team. Treatment decisions should be individualized; this overview is educational and is not a substitute for medical advice.

Sources: National Cancer Institute, “Cancer Immunotherapy,” https://www.cancer.gov/about-cancer/treatment/types/immunotherapy; National Cancer Institute, “The Tumor Microenvironment,” https://www.cancer.gov/about-cancer/treatment/research/tumor-microenvironment; American Cancer Society, “HER2 Status,” https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html; Salgado et al., “The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014,” Annals of Oncology, https://doi.org/10.1093/annonc/mdu450; Schmid et al., “Pembrolizumab for Early Triple-Negative Breast Cancer,” New England Journal of Medicine, 2020, https://doi.org/10.1056/NEJMoa1910549; U.S. Food and Drug Administration, “FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer,” https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer; Cortes et al., “Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer,” New England Journal of Medicine, 2022, https://doi.org/10.1056/NEJMoa2202809; U.S. Food and Drug Administration, “FDA approves pembrolizumab for locally recurrent unresectable or metastatic triple-negative breast cancer,” https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-locally-recurrent-unresectable-or-metastatic-triple-negative-breast-cancer.